Ultrastable PLGA-Coated 177 Lu-Microspheres for Radioembolization Therapy of Hepatocellular Carcinoma
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Shuo Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Polylactic Acid-Polyglycolic Acid Copolymer, Microspheres. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions, Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University.
Abstract (Originalsprache)
Transarterial radioembolization (TARE) is a highly effective localized radionuclide therapy that has been successfully used to treat hepatocellular carcinoma (HCC). Extensive research has been conducted on the use of radioactive microspheres (MSs) in TARE, and the development of ideal radioactive MSs is crucial for clinical trials and patient treatment. This study presents the development of a radioactive MS for TARE of HCC. These MSs, referred to as 177Lu-MS@PLGA, consist of poly(lactic-co-glycolic acid) (PLGA) copolymer and radioactive silica MSs, labeled with 177Lu and then coated with PLGA. It has an extremely high level of radiostability. Cellular experiments have shown that it can cause DNA double-strand breaks, leading to cell death. In vivo radiostability of 177Lu-MS@PLGA is demonstrated by microSPECT/CT imaging. In addition, the antitumor study has shown that TARE of 177Lu-MS@PLGA can effectively restrain tumor growth without harmful side effects. Thus, 177Lu-MS@PLGA exhibits significant potential as a radioactive MS for the treatment of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University,…
- Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
ORCID-Profile: Ran Zhu, Guanglin Wang
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Interdisciplinary Basic Frontier Innovation Program of Suzhou Medical College of Soochow University
Zitieren
APA
Jin, S., Huang, J., Dong, Y., Hu, D., Sun, J., Li, Z., Zhong, B. Y., Liu, Z., Zhu, R., & Wang, G. (2024). Ultrastable PLGA-Coated 177 Lu-Microspheres for Radioembolization Therapy of Hepatocellular Carcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00138
Vancouver
Jin S, Huang J, Dong Y, Hu D, Sun J, Li Z, et al. Ultrastable PLGA-Coated 177 Lu-Microspheres for Radioembolization Therapy of Hepatocellular Carcinoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00138
BibTeX
@article{Jin2024,
author = {Jin, Shuo and Huang, Jintao and Dong, Yi and Hu, Di and Sun, Jing and Li, Zhihao and Zhong, Bin-Yan and Liu, Zhiyong and Zhu, Ran and Wang, Guanglin},
title = {Ultrastable PLGA-Coated 177 Lu-Microspheres for Radioembolization Therapy of Hepatocellular Carcinoma},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00138}
}
EUVIMED